Ventripoint Diagnostics Ltd. (TSX-V:VPT, OTC:VPTDF) announced that its strategic partner, Lishman Global Inc., has formally submitted Ventripoint’s VMS+™ 4.0 system to China’s National Medical Products Administration (NMPA) for regulatory approval. The submission qualifies for the NMPA’s “green channel” pathway, an expedited review process designed to accelerate approval of innovative medical technologies addressing significant clinical needs, which is expected to streamline the regulatory timeline and facilitate faster market access.
This submission represents a significant milestone in Ventripoint’s global expansion strategy and reflects growing demand for advanced, accessible cardiac imaging solutions in China, one of the world’s largest healthcare markets. Cardiovascular disease is the leading cause of mortality in China, affecting an estimated 330 million patients. Echocardiography is the most widely used cardiac imaging modality due to its cost-effectiveness and scalability, but variability in interpretation and limited access to MRI have created a strong need for AI-driven tools to improve diagnostic accuracy.
Ventripoint’s VMS+™ 4.0 addresses this need by providing MRI-equivalent volumetric measurements using standard 2D echocardiography. Powered by the company’s proprietary Knowledge Based Reconstruction technology, the platform enables clinicians to assess all four heart chambers with high accuracy, supporting diagnosis and management of congenital heart defects, heart failure, pulmonary hypertension, cardiotoxicity, and valvular disease.
“We are excited to take this important step toward bringing VMS+™ 4.0 to the Chinese market,” said Paul Gibson, Chief Technology Officer of Lishman Global Inc. “Qualification for the NMPA’s green channel underscores the clinical relevance and innovation of VMS+™ 4.0 and provides a clear pathway to accelerated adoption.”
Hugh MacNaught, President and CEO of Ventripoint Diagnostics, added: “China is one of the most important cardiac care markets in the world. With the benefit of an expedited review pathway, we are well positioned to bring VMS+™ 4.0 to clinicians and patients more quickly.” The company will provide further updates as the regulatory review process progresses.
Ventripoint is an industry leader in applying AI to echocardiography, with VMS+ products powered by Knowledge Based Reconstruction technology. The system is compatible with all ultrasound vendors and has regulatory approvals in the U.S., Europe, and Canada. Lishman Global, established in 2012, assists foreign companies in navigating China’s regulatory and distribution channels.
For further information, contact Hugh MacNaught at hmacnaught@ventripoint.com or 604-671-4201. Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy of this release.
This news release contains forward-looking statements based on expectations and assumptions. Actual results may differ materially due to risks detailed in the company’s most recent annual management’s discussion and analysis available on SEDAR at www.sedar.com. The company undertakes no obligation to update forward-looking statements unless required by law.
